Please amend the claims as follows:

1-9. (Cancelled without prejudice)

10. (Amended) A method for preventing and curing [[dermopathy]] <u>cutaneous</u> <u>inflammation</u> in a mammal which comprises administering thereto an effective amount of a dermatological agent for external use containing a chromanol glycoside represented by the following general formula (1)

$$R^{5}O$$
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{5}
 $R^{$

[[(]]wherein R^1 , R^2 , R^3 , and R^4 , which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R^5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, [[x]] \underline{X} represents a monosaccharic residue or an oligosaccharic residue, which may have [[optionally having]] the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6[[)]].

- 11. (Amended) The method of claim 10 wherein said chromanol glycoside is 2-(α -D-glycopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-galactopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-fructofuranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, and 2-(α -D-mannopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol.
- 12. (Amended) A method for preventing and curing [[a disorder]] <u>inflammation</u> caused by ultraviolet light in a mammal which comprises administering thereto an effective amount of a dermatological agent for external use containing a chromanol glycoside represented by the following general formula (1)

$$R^{5}O$$
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{5}
 R^{5}
 R^{2}
 R^{3}
 R^{4}
 R^{5}
 $R^{$



[[(]]wherein R^1 , R^2 , R^3 , and R^4 , which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R^5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, [[x]] \underline{X} represents a monosaccharic residue or an oligosaccharic residue, which may have [[optionally having]] the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6[[)]].

- 13. (Amended) The method of claim 12 wherein said chromanol glycoside is 2-(α -D-glycopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-galactopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-fructofuranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, and 2-(α -D-mannopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol.
- 14. (Amended) A method for preventing and [[allowing]] <u>allaying</u> the deposition of pigment in the skin in a mammal which comprises administering thereto an effective amount of a dermatological agent for external use containing a chromanol glycoside represented by the following general formula (1)

$$R^{5}O$$
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{4}
 R^{5}
 $R^{$

[[(]]wherein R^1 , R^2 , R^3 , and R^4 , which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R^5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, [[x]] \underline{X} represents a monosaccharic residue or an oligosaccharic residue, which may have [[optionally having]] the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6[[)]].

- 15. (Amended) The method of claim 14 wherein said chromanol glycoside is 2-(α -D-glycopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-galactopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-fructofuranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, and 2-(α -D-mannopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol.
- 16. (Amended) A method for [[beautifying the]] whitening skin [[in white]] in a mammal which comprises administering thereto an effective amount of a dermatological agent for external use containing a chromanol glycoside represented by the following general formula (1)

$$R^{5}O$$
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{5}
 $R^{$

[[(]]wherein R^1 , R^2 , R^3 , and R^4 , which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R^5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, [[x]] \underline{X} represents a monosaccharic residue or an oligosaccharic residue, which may have [[optionally having]] the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6[[)]].

- 17. (Amended) The method of claim 16 wherein said chromanol glycoside is 2-(α -D-glycopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-galactopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-fructofuranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, and 2-(α -D-mannopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol.
- 18. (Amended) A method for preventing the [[senescence of the skin]] the formation of wrinkles and sags caused by ultraviolet light in a mammal which comprises administering thereto an effective amount of a dermatological agent for external use containing a chromanol glycoside represented by the following general formula (1)

$$R^{5}O$$
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{4}
 $R^{5}O$
 R^{4}
 $R^{5}O$
 R^{4}
 $R^{5}O$
 R^{4}
 $R^{5}O$
 R^{4}
 $R^{5}O$
 $R^{5}O$

[[(]]wherein R^1 , R^2 , R^3 , and R^4 , which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R^5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, [[x]] \underline{X} represents a monosaccharic residue or an oligosaccharic residue, which may have [[optionally having]] the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6[[)]].

19. (Amended) The method of claim 18 wherein said chromanol glycoside is $2-(\alpha-D-glycopyranosyl)$ methyl-2,5,7,8-tetramethyl chroman-6-ol, $2-(\beta-D-galactopyranosyl)$ methyl-

2,5,7,8-tetramethyl chroman-6-ol, $2-(\beta-D-fructofuranosyl)$ methyl-2,5,7,8-tetramethyl chroman-6-ol, and $2-(\alpha-D-mannopyranosyl)$ methyl-2,5,7,8-tetramethyl chroman-6-ol.

20. (Amended) A method for [[activating cells]] <u>promoting growth of cells</u> in a mammal which comprises administering thereto an effective amount of a dermatological agent for external use containing a chromanol glycoside represented by the following general formula (1)

$$R^{5}O$$
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{2}
 R^{3}
 R^{4}
 R^{4}
 R^{5}
 $R^{$

[[(]]wherein R^1 , R^2 , R^3 , and R^4 , which may be the same or different, each represent a hydrogen atom or a lower alkyl group, R^5 represents a hydrogen atom, a lower alkyl group, or a lower acyl group, [[x]] \underline{X} represents a monosaccharic residue or an oligosaccharic residue, which may have [[optionally having]] the hydrogen atom of the hydroxyl group in the saccharic residue substituted with a lower alkyl group or a lower acyl group, n represents an integer in the range of 0-6, and m represents an integer in the range of 1-6).

21. (Amended) The method of claim 20 wherein said chromanol glycoside is 2-(α -D-glycopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-galactopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, 2-(β -D-fructofuranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol, and 2-(α -D-mannopyranosyl)methyl-2,5,7,8-tetramethyl chroman-6-ol.